Mark S. Graham

Array ( [id] => 11429333 [patent_doc_number] => 09567642 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-14 [patent_title] => 'Methods and products related to targeted cancer therapy' [patent_app_type] => utility [patent_app_number] => 14/376482 [patent_app_country] => US [patent_app_date] => 2013-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 23 [patent_no_of_words] => 11257 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14376482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9427368 [patent_doc_number] => 08703441 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-04-22 [patent_title] => 'Monoclonal antibodies against PCBP-1 antigens, and uses therefor' [patent_app_type] => utility [patent_app_number] => 13/739931 [patent_app_country] => US [patent_app_date] => 2013-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 53 [patent_no_of_words] => 27447 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13739931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10331994 [patent_doc_number] => 20150216998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'ENDO180-TARGETED PARTICLES FOR SELECTIVE DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS' [patent_app_type] => utility [patent_app_number] => 14/367922 [patent_app_country] => US [patent_app_date] => 2012-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 27455 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14367922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9468421 [patent_doc_number] => 08722051 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-05-13 [patent_title] => 'Tweak receptor' [patent_app_type] => utility [patent_app_number] => 13/720785 [patent_app_country] => US [patent_app_date] => 2012-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 19555 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13720785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10325772 [patent_doc_number] => 20150210777 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'GLYCOPROTEIN' [patent_app_type] => utility [patent_app_number] => 14/365014 [patent_app_country] => US [patent_app_date] => 2012-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 16768 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14365014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9720252 [patent_doc_number] => 20140255954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-11 [patent_title] => 'METHOD OF BREAST CANCER DETECTION' [patent_app_type] => utility [patent_app_number] => 14/352668 [patent_app_country] => US [patent_app_date] => 2012-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 13949 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14352668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8767069 [patent_doc_number] => 20130095106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-18 [patent_title] => 'USE OF TRIFUNCTIONAL BISPECIFIC AND TRISPECIFIC ANTIBODIES FOR THE TREATMENT OF MALIGNANT ASCITES' [patent_app_type] => utility [patent_app_number] => 13/632737 [patent_app_country] => US [patent_app_date] => 2012-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 6757 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13632737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9134336 [patent_doc_number] => 20130295050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-07 [patent_title] => 'ANTI-IGF-I RECEPTOR ANTIBODIES, DNAS, VECTORS, HOST CELLS AND GENETIC CONSTRUCTS' [patent_app_type] => utility [patent_app_number] => 13/616832 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 17380 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13616832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8697742 [patent_doc_number] => 20130059751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-07 [patent_title] => 'GENE FAMILY (LBFL313) ASSOCIATED WITH PANCREATIC CANCER' [patent_app_type] => utility [patent_app_number] => 13/591301 [patent_app_country] => US [patent_app_date] => 2012-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 18594 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13591301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8566063 [patent_doc_number] => 20120328634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-27 [patent_title] => 'Immunoconjugates with an Intracellularly-Cleavable Linkage' [patent_app_type] => utility [patent_app_number] => 13/586281 [patent_app_country] => US [patent_app_date] => 2012-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11279 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13586281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8405457 [patent_doc_number] => 20120237514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-20 [patent_title] => 'VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/485827 [patent_app_country] => US [patent_app_date] => 2012-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 15047 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13485827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9197725 [patent_doc_number] => 20130337039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-19 [patent_title] => 'Internalizing ErBB2 Antibodies' [patent_app_type] => utility [patent_app_number] => 13/441651 [patent_app_country] => US [patent_app_date] => 2012-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 28745 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13441651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11408964 [patent_doc_number] => 09556256 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-31 [patent_title] => 'Inhibition of cancer metastasis' [patent_app_type] => utility [patent_app_number] => 13/440137 [patent_app_country] => US [patent_app_date] => 2012-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 20 [patent_no_of_words] => 16566 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13440137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8566508 [patent_doc_number] => 20120329079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-27 [patent_title] => 'Pro108 Antibody Compositions and Methods of Use and Use of Pro108 to Assess Cancer Risk' [patent_app_type] => utility [patent_app_number] => 13/438427 [patent_app_country] => US [patent_app_date] => 2012-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 50349 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13438427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8405519 [patent_doc_number] => 20120237569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-20 [patent_title] => 'EMULSIFIED COMPOSITION FOR DILUTION AND CANCER VACCINE COMPOSITION' [patent_app_type] => utility [patent_app_number] => 13/432915 [patent_app_country] => US [patent_app_date] => 2012-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 11998 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13432915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8865595 [patent_doc_number] => 20130149299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-13 [patent_title] => 'DOSAGES FOR TREATMENT WITH ANTI-EGFR ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/415271 [patent_app_country] => US [patent_app_date] => 2012-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 26022 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13415271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8429656 [patent_doc_number] => 20120251530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-04 [patent_title] => 'COMBINATION THERAPY OF HER EXPRESSING TUMORS' [patent_app_type] => utility [patent_app_number] => 13/413062 [patent_app_country] => US [patent_app_date] => 2012-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 62295 [patent_no_of_claims] => 60 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13413062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8452760 [patent_doc_number] => 20120263707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-18 [patent_title] => 'Broad Spectrum ErbB Ligand Binding Molecules and Methods for Preparing and Using Them' [patent_app_type] => utility [patent_app_number] => 13/359755 [patent_app_country] => US [patent_app_date] => 2012-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 25204 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13359755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8196839 [patent_doc_number] => 20120121505 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-17 [patent_title] => 'THERAPEUTIC COMPOSITIONS AND METHODS' [patent_app_type] => utility [patent_app_number] => 13/349481 [patent_app_country] => US [patent_app_date] => 2012-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 24736 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0121/20120121505.pdf [firstpage_image] =>[orig_patent_app_number] => 13349481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9269784 [patent_doc_number] => 20140024702 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-23 [patent_title] => 'CANCER GENE THERAPY USING NUCLEIC ACIDS ENCODING US28 AND G-PROTEIN' [patent_app_type] => utility [patent_app_number] => 13/993038 [patent_app_country] => US [patent_app_date] => 2011-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 7211 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13993038 [rel_patent_id] =>[rel_patent_doc_number] =>)